HMGCS1: How Tumors Repair Immune Damage and Escape Killing
Cancer cells are not passive targets. When cytotoxic T cells or NK cells attack, they punch holes in the tumor membrane using perforin. A new Nature Communications study reveals that tumors actively repair this damage through a metabolic defense mechanism centered on HMGCS1-driven cholesterol synthesis.
Researchers screened 111 metabolic enzymes and identified HMGCS1, the first committed enzyme in the mevalonate/cholesterol pathway, as the strongest regulator of plasma membrane repair. Loss of HMGCS1 dramatically increased membrane damage following perforin-like injury and sensitized tumor cells to immune attack.
Mechanistically, HMGCS1 increases de novo cholesterol synthesis, which supports membrane repair through two complementary functions:
🔹 Structural role — supplies cholesterol as a building block for membrane reconstruction.
🔹 Signaling role — cholesterol directly binds the ESCRT repair protein CHMP4B, promoting its localization to damaged plasma membranes and accelerating repair.
Without HMGCS1:
• Cholesterol levels fall
• CHMP4B membrane recruitment decreases
• ESCRT-mediated repair fails
• Perforin pores persist
• Granzyme entry increases
• Tumor cell killing is enhanced
The translational implications are striking.
HMGCS1 depletion significantly improved:
✅ NK-cell therapy
✅ CAR-T therapy
✅ Anti-PD-1 immunotherapy
across multiple in vitro and in vivo lung cancer models. Tumors lacking HMGCS1 became markedly more sensitive to immune-mediated destruction.
The study also uncovered an upstream regulatory circuit. c-Jun activation—driven by inflammatory cytokines, hypoxia, and oncogenic mutations such as EGFR L858R, KRAS G12V, and BRAF V600E—induces HMGCS1 expression. This links oncogenic signaling directly to immune evasion through metabolic membrane repair.
Perhaps most clinically relevant, lung cancer patients who failed anti-PD-1 therapy showed:
• Higher HMGCS1 expression
• Increased cholesterol accumulation
• Greater plasma membrane CHMP4B localization
• Stronger c-Jun activation
These findings suggest that HMGCS1 may function both as a predictive biomarker and as a therapeutic target.
Rather than suppressing immune cells directly, tumors can survive by rapidly repairing immune-inflicted membrane damage. Blocking this repair system may expose a previously unrecognized vulnerability in immunotherapy-resistant cancers.
Reference
Zhang Y, Wang S, Luo T, et al. HMGCS1 drives cholesterol-dependent membrane repair and shields tumor cells from lymphocyte attack. Nature Communications. 2026. DOI: 10.1038/s41467-026-74022-y.
#CancerImmunology #HMGCS1 #CholesterolMetabolism #ESCRT #CHMP4B #CAR_T #NKCells #PD1 #TumorImmuneEvasion #NatureCommunications